How to Buy IPCA Laboratories Ltd Shares?
You can easily buy the stocks/shares of IPCA Laboratories Ltd (IPCALAB) on Tickertape or through broker platform by opening a Demat & Trading account onlineWhat is the Share Price of IPCA Laboratories Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of IPCALAB as on 15th May 2025 is ₹1419.80What is the return on IPCA Laboratories Ltd share?
The past returns of IPCA Laboratories Ltd (IPCALAB) share are- Past 1 week: N/A
- Past 1 month: -55.45
- Past 3 months: 5.32
- Past 6 months: -10.80
- Past 1 year: 14.05
- Past 3 years: 58.30
- Past 5 years: 71.10
What is the Dividend yield % on IPCA Laboratories Ltd share?
The current dividend yield of IPCA Laboratories Ltd (IPCALAB) is 0.29What is the Market Cap of IPCA Laboratories Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of IPCA Laboratories Ltd (IPCALAB) is ₹34671.03Cr as of 15th May 2025What is the 52 Week High and Low of IPCA Laboratories Ltd?
The 52-week high and low of IPCA Laboratories Ltd (IPCALAB) is ₹1755.90 and ₹1052.What is the PE and PB ratio of IPCA Laboratories Ltd?
The P/E (price-to-earnings) and P/B (price-to-book) ratios of IPCA Laboratories Ltd are 47.00 and 4.49 respectively.Which sector does IPCA Laboratories Ltd belong to?
IPCA Laboratories Ltd (IPCALAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.What are the peers or stocks similar to IPCA Laboratories Ltd?
The peers or stocks similar to IPCA Laboratories Ltd are: and many others.Can't decide whether or not to buy IPCA Laboratories Ltd?
Worry no more! Login to Tickertape and check out IPCA Laboratories Ltd (IPCALAB) scorecard & all the relevant insights today5. Test Stocks FAQ What is the 52 Week High and Low of IPCA Laboratories Ltd?
The 52-week high and low of IPCA Laboratories Ltd (IPCALAB) is ₹1755.90 and ₹1052.1. Test Stocks FAQ for IPCA Laboratories Ltd Shares?
You can easily buy the stocks/shares of IPCA Laboratories Ltd (IPCALAB) on Tickertape or through broker platform by opening a Google & Trading account online3. Test Stocks FAQ What is the Share Price of IPCA Laboratories Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of IPCALAB as on 15th May 2025 is ₹1419.80
IPCA Laboratories Ltd
IPCALAB Share Price
1,419.800.10% (+1.40)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
IPCALAB Performance & Key Metrics
IPCALAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 47.00 | 4.49 | 0.29% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.21 | 6.66 | 0.83% |
IPCALAB Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
IPCALAB Company Profile
Ipca Laboratories Limited is engaged in pharmaceuticals business. The Company is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs).
SUNPHARMA
PE Ratio
37.00
37.00
1Y Return
11.72%
11.72%
Buy Reco %
89.19
89.19
CIPLA
PE Ratio
23.03
23.03
1Y Return
2.55%
2.55%
Buy Reco %
71.05
71.05
DRREDDY
PE Ratio
20.02
20.02
1Y Return
11.76%
11.76%
Buy Reco %
82.05
82.05
TORNTPHARM
PE Ratio
57.53
57.53
1Y Return
13.13%
13.13%
Buy Reco %
67.74
67.74
MANKIND
PE Ratio
49.29
49.29
1Y Return
6.30%
6.30%
Buy Reco %
—
—
IPCALAB Sentiment Analysis
IPCALAB Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
IPCALAB Stock Summary · January 2025
Company is navigating a complex landscape characterized by declining market share in deposits, challenges in meeting Priority Sector Lending (PSL) obligations, and fluctuations in current account flows. Despite these hurdles, the bank is focusing on enhancing customer engagement and service delivery to drive deposit growth, with recent monthly inflows showing a positive trend. The management emphasizes a strategic approach to maintaining profitability over aggressive expansion, particularly in light of competitive pressures and a tight liquidity environment. Efforts to improve operational efficiencies through digitization and a commitment to stable cost management are underway, alongside a proactive strategy to reduce borrowings and strengthen the balance sheet. Overall, while facing short-term challenges, the bank remains optimistic about future performance and is committed to achieving sustainable growth through strategic investments and improved customer outreach.
IPCALAB Stock Growth Drivers
IPCALAB Stock Growth Drivers
4Focus on Sustainable Growth
Company is prioritizing profitable growth over mere expansion, emphasizing a strategy that encourages ground-level teams
Stable Financial Metrics
The company has maintained a return on assets (ROA) of 1.9% post-merger, showcasing stability in
IPCALAB Stock Challenges
IPCALAB Stock Challenges
2Deposit Growth Shortfalls
The company has experienced deposit growth that has not met expectations, attributed to seasonal trends
Loan Growth Concerns
There is uncertainty regarding the company's loan deposit ratio (LDR) and its implications for loan
IPCALAB Forecast
What are forecasts?
What are forecasts?
Forecasting uses historical data as inputs to make informed predictive estimates determining the direction of future trends. Price, revenue & earnings forecasts represent where the stock level, business prospects and profits are potentially expected to be at the end of the forecast period
IPCALAB Forecasts
Price
Revenue
Earnings
IPCALAB Share Price Forecast
IPCALAB Share Price Forecast
2025
Current
₹1,368.40
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹1,368.40
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
IPCALAB Company Revenue Forecast
IPCALAB Company Revenue Forecast
2025
Current
₹9.03
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹9.03
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
IPCALAB Stock EPS (Earnings Per Share) Forecast
IPCALAB Stock EPS (Earnings Per Share) Forecast
2025
Current
₹29.08
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹29.08
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
IPCALAB
IPCALAB
Income
Balance Sheet
Cash Flow
Annual Normal View
IPCALAB Income Statement
IPCALAB Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,168.94 | 3,299.56 | 3,803.37 | 4,686.03 | 5,482.83 | 5,896.36 | 6,369.94 | 7,897.82 | 9,032.39 | 9,032.39 | ||||||||||
Raw Materials | 1,115.71 | 1,101.28 | 1,355.15 | 1,820.25 | 1,923.09 | 2,144.50 | 2,205.84 | 2,706.39 | 7,418.50 | 7,418.50 | ||||||||||
| Power & Fuel Cost | 151.00 | 161.92 | 176.50 | 201.22 | 207.10 | 242.12 | 283.74 | 333.97 | ||||||||||||
| Employee Cost | 695.98 | 735.88 | 787.40 | 921.23 | 1,013.57 | 1,177.39 | 1,287.64 | 1,708.43 | ||||||||||||
| Selling & Administrative Expenses | 596.75 | 598.72 | 524.85 | 545.44 | 575.16 | 641.87 | 704.69 | 853.53 | ||||||||||||
| Operating & Other expenses | 147.58 | 205.93 | 208.35 | 228.73 | 153.49 | 311.14 | 832.99 | 954.84 | ||||||||||||
EBITDA | 461.92 | 495.83 | 751.12 | 969.16 | 1,610.42 | 1,379.34 | 1,055.04 | 1,340.66 | 1,613.89 | 1,613.89 | ||||||||||
| Depreciation/Amortization | 172.95 | 177.73 | 182.42 | 210.50 | 209.17 | 232.42 | 261.56 | 357.24 | 397.82 | 397.82 | ||||||||||
| PBIT | 288.97 | 318.10 | 568.70 | 758.66 | 1,401.25 | 1,146.92 | 793.48 | 983.42 | 1,216.07 | 1,216.07 | ||||||||||
| Interest & Other Items | 26.91 | 27.57 | 22.24 | 19.77 | 12.27 | 11.20 | 48.19 | 140.75 | 84.93 | 84.93 | ||||||||||
| PBT | 262.06 | 290.53 | 546.46 | 738.89 | 1,388.98 | 1,135.72 | 745.29 | 842.67 | 1,131.14 | 1,131.14 | ||||||||||
| Taxes & Other Items | 67.52 | 51.11 | 101.63 | 132.57 | 248.97 | 251.64 | 273.97 | 295.32 | 393.46 | 393.46 | ||||||||||
| Net Income | 194.54 | 239.42 | 444.83 | 606.32 | 1,140.01 | 884.08 | 471.32 | 547.35 | 737.68 | 737.68 | ||||||||||
| EPS | 7.71 | 12.65 | 35.23 | 47.99 | 59.99 | 34.85 | 18.58 | 21.57 | 29.08 | 29.08 | ||||||||||
| DPS | 0.50 | 1.00 | 3.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | ||||||||||
| Payout ratio | 0.06 | 0.08 | 0.09 | 0.10 | 0.07 | 0.11 | 0.22 | 0.19 | 0.14 | 0.14 |
IPCALAB Company Updates
FY 2023FY 2023
IPCALAB Stock Peers
What are peers and why compare against them?
What are peers and why compare against them?
A stock's peers are companies which have similar business interests, operations and belong to the same industry sector. Comparing various metrics against peers can give valuable insights on whether the company's stock is over/under-valued and the company's growth outlook vs the industry as a whole
IPCALAB Past Performance & Peer Comparison
IPCALAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| IPCA Laboratories Ltd | 47.00 | 4.49 | 0.29% |
| Sun Pharmaceutical Industries Ltd | 37.00 | 6.03 | 0.95% |
| Cipla Ltd | 23.03 | 4.53 | 1.06% |
| Dr Reddy's Laboratories Ltd | 20.02 | 4.01 | 0.59% |
IPCALAB Stock Price Comparison
Compare IPCALAB with any stock or ETFCompare IPCALAB with any stock or ETF
IPCALAB
IPCALAB Holdings
IPCALAB Shareholdings
What are shareholdings?
What are shareholdings?
Apart from retail investors, a company’s shares are held by promoters, foreign & domestic institutions (large investors) and mutual funds. Promoters are the ship captains and control the company’s direction. Along with institutional and mutual fund holdings, a change in their holdings can indicate performance outlook for the stock
IPCALAB Promoter Holdings Trend
IPCALAB Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 1.58%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
IPCALAB Institutional Holdings Trend
IPCALAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
IPCALAB Shareholding Pattern
IPCALAB Shareholding Pattern
IPCALAB Shareholding History
IPCALAB Shareholding History
Foreign Institutions
Mutual Funds Invested in IPCALAB
Mutual Funds Invested in IPCALAB
No mutual funds holding trends are available
Top 5 Mutual Funds holding IPCA Laboratories Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 7.3684% | Percentage of the fund’s portfolio invested in the stock 3.20% | Change in the portfolio weight of the stock over the last 3 months 3.20% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 6/77 (+8) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 4.6727% | Percentage of the fund’s portfolio invested in the stock 3.03% | Change in the portfolio weight of the stock over the last 3 months -0.36% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 3/69 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 2.1852% | Percentage of the fund’s portfolio invested in the stock 4.05% | Change in the portfolio weight of the stock over the last 3 months 4.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 3/57 (+10) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing IPCALAB stock
smallcases containing IPCALAB stock
Looks like this stock is not in any smallcase yet.
IPCALAB Events
IPCALAB Events
IPCALAB Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
IPCALAB has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.29%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.93 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
What are dividends?
What are dividends?
Dividends are a portion of earnings that a company distributes to all its shareholders every year. Dividend return is one of the most important things to be considered while investing for long term. It’s the additional return on top of what investors earn through price appreciation
IPCALAB Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
IPCALAB has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.29%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.93 every year
IPCALAB Upcoming Dividends
IPCALAB Upcoming Dividends
No upcoming dividends are available
IPCALAB Past Dividends
IPCALAB Past Dividends
Cash Dividend
Ex DateEx DateNov 27, 2024
Interim
Interim | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Nov 27, 2024
Cash Dividend
Ex DateEx DateAug 6, 2024
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Aug 6, 2024
Cash Dividend
Ex DateEx DateNov 21, 2023
Interim
Interim | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Nov 21, 2023
Cash Dividend
Ex DateEx DateNov 22, 2022
Interim
Interim | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Nov 22, 2022
Cash Dividend
Ex DateEx DateNov 22, 2021
Interim
Interim | Div/Share: ₹8.00
Dividend/Share
₹8.00
Ex DateEx Date
Nov 22, 2021
IPCALAB Stock News & Opinions
IPCALAB Stock News & Opinions
Articles & Videos
Spotlight
Ipca Laboratories Ltd soars 1.25%, Gains for third straight session
Ipca Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 1406.8, up 1.25% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.28% on the day, quoting at 25069.95. The Sensex is at 82276.06, down 0.29%. Ipca Laboratories Ltd has added around 0.19% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has added around 4.05% in last one month and is currently quoting at 22057.15, up 0.76% on the day. The volume in the stock stood at 1.55 lakh shares today, compared to the daily average of 2.94 lakh shares in last one month.The PE of the stock is 42.27 based on TTM earnings ending March 25.Powered by Capital Market - Live
3 days agoCapital Market - Live
Earnings
Ipca Laboratories consolidated net profit rises 13.81% in the March 2025 quarter
Net profit of Ipca Laboratories rose 13.81% to Rs 67.82 crore in the quarter ended March 2025 as against Rs 59.59 crore during the previous quarter ended March 2024. Sales rose 10.51% to Rs 2246.69 crore in the quarter ended March 2025 as against Rs 2033.03 crore during the previous quarter ended March 2024. For the full year,net profit rose 34.77% to Rs 737.68 crore in the year ended March 2025 as against Rs 547.35 crore during the previous year ended March 2024. Sales rose 16.02% to Rs 8939.59 crore in the year ended March 2025 as against Rs 7705.04 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales2246.692033.03 11 8939.597705.04 16 OPM %19.0915.83 -19.3117.15 - PBDT433.17311.45 39 1734.011307.66 33 PBT333.05213.32 56 1336.19950.42 41 NP67.8259.59 14 737.68547.35 35 Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Board of Ipca Laboratories recommends final dividend
Ipca Laboratories announced that the Board of Directors of the Company at its meeting held on 29 May 2025, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 200%) , subject to the approval of the shareholders.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Ipca Laboratories to announce Quarterly Result
Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 29 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Ipca Laboratories now holds 100% stake in Unichem Laboratories, Ireland
Ipca Laboratories announced that 100% of the paid-up equity share capital of Unichem Laboratories, Ireland is transferred to Ipca Laboratories and, therefore, Unichem Laboratories, Ireland has now become a wholly owned subsidiary of the Company. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Ipca Laboratories appoints President ' Human Resources
Ipca Laboratories has appointed Saidutta Nanda as President ' Human Resources of the company with effect from 3 March 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Spotlight
Ipca Laboratories Ltd down for fifth straight session
Ipca Laboratories Ltd is down for a fifth straight session today. The stock is quoting at Rs 1356.5, down 0.89% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 1.84% on the day, quoting at 22131.1. The Sensex is at 73233.39, down 1.85%.Ipca Laboratories Ltd has lost around 6.01% in last one month.Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has eased around 6.27% in last one month and is currently quoting at 20201.25, down 1.81% on the day. The volume in the stock stood at 1.28 lakh shares today, compared to the daily average of 4.91 lakh shares in last one month.The PE of the stock is 41.97 based on TTM earnings ending December 24.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Ipca Laboratories consolidated net profit rises 37.95% in the December 2024 quarter
Net profit of Ipca Laboratories rose 37.95% to Rs 248.14 crore in the quarter ended December 2024 as against Rs 179.88 crore during the previous quarter ended December 2023. Sales rose 9.38% to Rs 2245.37 crore in the quarter ended December 2024 as against Rs 2052.85 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales2245.372052.85 9 OPM %20.6216.12 - PBDT466.38319.93 46 PBT367.92220.43 67 NP248.14179.88 38 Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Ipca Labs spurts after Q3 PAT soars to Rs 267 cr
Revenue from operations jumped 10.34% YoY to Rs 1,662.68 crore in the quarter ended 31st December 2024. Profit before tax (PBT) increased 77.63% to Rs 355.52 crore in Q3 FY25 as compared with Rs 200.15 crore in Q3 FY24. EBITDA stood at Rs 446.07 crore in Q3 FY25, registering the growth of 35% as compared with Rs 330.52 crore in Q3 FY24. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) stood at 19.87% in Q3 FY25 as against at 16.10% in Q3 FY24. During the quarter, total formulations were at Rs 1,335.32 crore, up 10% YoY. Domestic business stood at Rs 877.17 crore (up 13% YoY). Total revenue from active pharmaceutical ingredient (API) stood at Rs 317.92 crore (up 12% YoY). revenue from domestic business stood at Rs 95.16 crore (up 22%) while exports were at Rs 222.76 crore (up 7%) during the period under review. Ipca Laboratories is an Indian multinational pharmaceutical company. It produces theobromine, acetylthiophene, and p-bromotoluene as active pharmaceutical ingredients (APIs). Ipca sells these APIs and their intermediates globally.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Ipca Laboratories to announce Quarterly Result
Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 13 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 15.74%, vs industry avg of 9.02%
Over the last 5 years, market share increased from 0.92% to 2.07%
Over the last 5 years, net income has grown at a yearly rate of 4.24%, vs industry avg of 15.29%